

Repurposing Phytochemicals as Anti-HIV Agents

Pratiksha Jadaun, Priyanka Khopkar and Smita Kulkarni*

Department of Virology, National AIDS Research Institute, 73, 'G' Block, MIDC, Bhosari, Pune-411026, India

*Corresponding author: Smita Kulkarni, National AIDS Research Institute (Indian Council of Medical Research, Govt. of India) 73, "G" – block, MIDC, Bhosari, Pune-411026, Maharashtra, India, Tel: +91-9881366239; E-mail: skulkarni@nariindia.org

Received date: December 01, 2016, Accepted date: December 13, 2016, Published date: December 22, 2016

Copyright: © 2016 Jadaun P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Phytochemicals play crucial role in inhibiting key enzymes involved in HIV-1 replication. Repurposing of phytochemical based anti-HIV drug discovery through cross screening approaches and modern techniques is essential to provide better leads. Anti-HIV leads translated through phytochemicals could overcome current challenges of HIV therapy. Considering the immense potential of phytochemicals, this article summarizes the present status of the research carried out on their anti-HIV activities, with its limitations and future directions to foster drug discovery.

Keywords: HIV; Phytochemical; Anti-HIV; Drug discovery; Screening; Alkaloids; Flavonoids; Terpenoids

Opinion

The HIV epidemic is receding globally with a 38% drop in new infections (UNAIDS, 2014); however, it continues to pose as a major global public health challenge. The goal of an effective vaccine still remains elusive. Anti-retroviral treatment (ART) has increased the life span of people living with HIV (PLHIV) and 14.9 million people globally are receiving ART (WHO, 2015). Even though the mainstream highly active anti-retroviral therapy (HAART) potently suppresses the plasma HIV-1 viral load, it is unable to eradicate HIV completely. Therefore, there is a lifelong requirement for ART which will decrease the morbidity due to drug toxicity and acquisition of resistance [1,2]. Considering this, there is a continuous need to explore safe and efficacious anti-retroviral agents; which is a challenge that needs to be addressed through integrated approaches [3,4]. Azidothymidine (AZT) - a NRTI drug was the first accidental breakthrough in HIV therapy in 1980's with its origin from cancer research on phytochemicals [5]. Acyclovir, Valacyclovir and various HIV protease inhibitors are subsequent statutory examples following this trend [6,7]. This can be attributed to the fact that the chemical novelty for chemical scaffolds in natural products is 40% higher than any other source [8]. Although natural products are extensively studied for anti-HIV activity, majority of these studies are restricted to preliminary screenings that aren't pursued to the molecular level with allied approaches for substantiated outcomes. Thus, we would like to give particular emphasis on a widened and upgraded exploratory approach for phytochemical research using modernized tools to catalyze drug discovery for HIV and HIV associated co-morbidities.

Phytochemicals and anti-HIV research

A significant number of literary reports suggest that various phytochemicals derived from numerous plant extracts possess anti-HIV activity [9].

Ethnopharmacological screening of medicinal plants has delivered various phytochemicals-biomolecules (alkaloids, flavonoids,

polyphenols, triterpenoids, etc.) possessing varied biological properties. A significant number of literary reports suggest that various phytochemicals derived from numerous plant extracts possess anti-HIV activity.




Figure 1: Diagrammatic representation of phytochemicals and their targets in the HIV replication cycle

These include the alkaloids (e.g. arnomoline, FK-3000) [10], polyphenols (e.g. Tanins-gallic acid, ellagic acid, gallotannins, galloylquinic acids) [11] and triterpenoids (e.g. cucurbitacins, other derivatives) that flank most of the events involved in HIV replication cycle by impairing CD4 and gp-120 binding, synthesis of glycoproteins and inhibition of the enzyme-glycosidases. They act at both, the early stage of HIV life cycle by inhibiting reverse transcriptase and at a later stage by inhibiting cellular fusion and syncytia formation. Hydroxycinnamic acid derivatives (eg. coumarins and its derivatives) form another class of phytochemicals reporting potential inhibition of HIV replication, specifically targeting the HIV reverse transcriptase [12]. Flavonoids are well known for antioxidant properties [13] and these are also potent HIV reverse transcriptase inhibitors [14]. Other

phytochemicals like lectins debilitate virus-cell fusion; lignins interfere with host virus integration and target HIV protease, glycosides, saponins and xanthenes act at reverse transcription and proteolytic post translational steps depicting anti-HIV activity [15]. A brief overview of the phytochemicals that possess anti-HIV activity, pinpointing the various stages of HIV life cycle has been given in graphical presentation (Figure 1).

Perusal of the literature reveals that some naturally derived phytochemical leads such as betulinic acid (PA-457) – also known as bevirimat, calanolides, crofelemer (CAS 148465-45-6), DCK (PA-334B), 3,5-di-O-caffeoylquinic acid, MX-3253, 4-methylumbelliferone and setarud (IMOD™) have shown preclinical therapeutic efficacies [16,17] and have reached to different phases of clinical trials as promising anti-HIV agents.

Future direction for phytochemical research and perspectives

Phytochemicals have been a rich source of compounds for drug leads. Even though more than 4,000 phytochemicals have been cataloged and classified based on the protective function and physico-chemical characteristics, only few have been explored so far. However in part, the reasons behind their limited use are restricted to boundary barriers and lack of insistence. Indigenous efforts are needed to access the natural biodiversity beyond the geographical boundaries and thorough perseverance of the reported studies with innovative technical advances is essential. Consistent with the other researchers, we opine that drug discovery from new natural sources needs more attention and exploration with a different view point. Furthermore, for enhanced implications, researchers' need to undertake evaluations and characterization of plants and plant constituents against disease based age old traditional claims arising from alternative medicine practitioners, with legitimate clinical findings. A systematic synchronization of the experience gathered in ethnopharmacology with authentic, high quality data existing in the natural product libraries may refine natural product screening approaches.

Nevertheless, appropriate biological target selection plays a crucial role in drug discovery. Screening physiological processes like macro and micro virus interactions that include glycosylation sites; antisense oligonucleotides or ribozymes targeting viral mRNAs; gene therapy approaches; immunotherapy; and so on needs to be counter fretted. Research on poorly understood antiviral potencies and modes-of-actions of various phytochemicals needs to be exploited for newer molecules. Cross screening approaches harnessing both 'serendipitous' screening strategies and rational drug design, as exemplified in the case of Zidovudine; Acyclovir, Valacyclovir and the HIV protease inhibitors needs to be strengthened with the medicinal chemists and biomedical researchers for new drugs from the phytochemical category [6,7,18].

With the emerging novel technologies, the existing natural products drug discovery platforms for phytochemical screenings warrant up gradations with the biology-oriented synthesis, activity profiling of extracts-structure activity relationship and integration of *in silico* approaches. Additional reformations about incorporating pharmaceutical properties-pharmacodynamics, pharmacokinetics studies, screening against additional viruses, which are less preferred over HIV-1 primary/lab adapted strains (eg. HIV-1 drug-resistant, HIV-2); use of new *in silico* approaches such as SELEX (US FDA guidelines) [19,20], receptor dependent QSAR (RD-QSAR) too needs attention. Up gradations of the *in vitro* assay platforms with additional holistic assays that tap the accessory genes of HIV (rev, protease and

tat), is the current necessity [21]. Refurbishing the existing bioassays with *in vivo* system, the use of humanized mice and bio imaging need to be strengthened and applied to preclinical HIV drug research along with ADME (absorption, distribution, metabolism, and elimination) profiles [22]. Phytochemicals offer an exciting potential for anti-HIV drug discovery, provided the technical mechanistic hindrances are overcome with improvements. Phytochemicals that have served as an important source of drugs in the past should not be overlooked in the 21st century. We conclude the article with the sense of optimism that with the tools available with the advent of technology when explored could lead to path-breaking drug discovery from phytochemicals in the field of HIV research.

Acknowledgements

This work is supported by the Department of Biotechnology [DBT, Grant No: BT/PR7827/MED/108/16/2013] and Indian Council of Medical Research [ICMR, Grant No: 5/7/828/12-RCH] Government of India.

Competing Interests

The author(s) declare that they have no competing interests.

References

1. Tang MW, Shafer RW (2012) HIV-1 antiretroviral resistance: scientific principles and clinical applications. *Drugs* 72: e1-25.
2. Stadel KM, Richman DD (2013) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. *Antivir Ther* 18: 115-123.
3. Engelman A, Cherepanov P (2012) The structural biology of HIV-1: mechanistic and therapeutic insights. *Nat Rev Microbiol* 10: 279-290.
4. Marcus KA, Sorbello A, Truffa M, Williams J, Raine JM, et al. (2012) Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV. *Curr Opin HIV AIDS* 7: 292-298.
5. Mitsuya H, Weinhold KJ, Furman PA, St Clair, Lehrman MH, et al. (1985) 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. *Proc Natl Acad Sci U S A* 82: 7096-7100.
6. Pattishall KH (1993) Discovery and Development of Zidovudine as the Cornerstone of Therapy to Control Human Immunodeficiency Virus Infection. *The Search for Antiviral Drugs* 23-43.
7. Vanpouille C, Lisco A, Grivel JC, Bassit LC, Kauffman RC, et al. (2015) Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial. *Clin Infect Dis* 60: 1708-1714.
8. Harvey A (2000) Strategies for discovering drugs from previously unexplored natural products. *Drug Discov Today* 5: 294-300.
9. Beutler JA (2009) Natural Products as a Foundation for Drug Discovery. *Curr Protoc Pharmacol* 46: 9-11.
10. Ma CM, Nakamura N, Miyashiro H, Hattori M, Komatsu K, et al. (2002) Screening of Chinese and Mongolian herbal drugs for anti-human immunodeficiency virus type 1 (HIV-1) activity. *Phytother Res* 16: 186-189.
11. Helfer M, Koppensteiner H, Schneider M, Rebenburg S, Forcisi S, et al. (2014) The root extract of the medicinal plant *Pelargonium sidoides* is a potent HIV-1 attachment inhibitor. *PLoS One* 9: e87487.
12. Kostova I (2006) Coumarins as inhibitors of HIV reverse transcriptase. *Curr HIV Res* 4: 347-363.
13. Wang Q, Ding ZH, Liu JK (2004) Xanthohumol, a novel anti-HIV-1 agent purified from *Hops Humulus lupulus*. *Antiviral research* 64: 189-194.

-
14. Seal A, Aykkal R, Babu RO (2011) Docking study of HIV-1 reverse transcriptase with phytochemicals. *Bioinformation* 5: 430-439.
 15. Chinsembu KC, Hedimbi M (2009) survey of plants with anti-HIV active compounds and their modes of action. *Medical Journal of Zambia* 36: 178-186.
 16. Saklani A, Kutty SK (2008) Plant-derived compounds in clinical trials. *Drug Discov Today* 13: 161-171.
 17. Zabihollahi R, Namazi R, Aghasadeghi MR, Esfahani AF, Sadat SM, et al. (2012) The in vitro anti-viral potential of Setarud (IMOD), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials. *Indian J Pharmacol* 44: 448-453.
 18. Sansom C (2009) Drug design: HIV, Molecules made to measure. *Chemistry World* 50: 51-53.
 19. Zimmermann B, Bilusic I, Lorenz C (2010) Genomic SELEX: a discovery tool for genomic aptamers. *Methods* 52: 125-132.
 20. Turi CE, Finley J, Shipley PR (2015) Metabolomics for phytochemical discovery: development of statistical approaches using a cranberry model system. *J Nat Prod* 78: 953-966.
 21. Kudo E, Taura M, Matsuda K (2013) Inhibition of HIV-1 replication by a tricyclic coumarin GUT-70 in acutely and chronically infected cells. *Bioorg Med Chem Lett* 23: 606-609.
 22. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. *Nat Rev Immunol* 7: 118-130.